Testing statin treatment in primary sclerosing cholangitis
Treatments studied
Part of Digestive system clinical trials.
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have a confirmed diagnosis of PSC
- If you’re in the comparison group, you have high cholesterol and a BMI under 25
- You have not already been taking statin medicine before starting the study
- You do not have liver overlap disease with autoimmune hepatitis
- Recent tests and other factors fit the study limits (for example, bilirubin not too high and liver enzymes not more than 5x normal)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
This study creates a national database for people diagnosed with primary sclerosing cholangitis (PSC). It may help researchers learn more about the condition by collecting health information from participants.
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.